Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma

    Jun-Hua Meng1, Ping Ni2, Yu-Ling Cao3, Yu Zhang2, Xiong Wang1, Hong Zhang4, Yong-Gang Chen1 Corresponding author

    1. 1Department of Pharmacy, Wuhan University Tongren Hospital (The Third Hospital of Wuhan), Wuhan, Hubei, CHINA.
    2. 2School of Pharmacy, Hubei University of Traditional Chinese Medicine, Wuhan, Hubei, CHINA.
    3. 3Department of Pharmacy, Wuhan ASIA General Hospital, Wuhan, Hubei, CHINA.
    4. 4Department of Pharmacy, The First People’s Hospital of Jiangxia District, Wuhan, Hubei, China.

    CORRESPONDENCE

    Yu Zhang

    School of Pharmacy, Hubei University of Traditional Chinese Medicine, Wuhan, Hubei, CHINA.

    390479135@qq.com

    Received: 10-02-2023; Accepted: 20-06-2023.

    Volume 20, Issue 1 · pp. 127–136 · PUBLISHED 2024 · DOI: 10.1177/09731296231189329

    View on Pharmacogn. Mag. original site ↗

    ABSTRACT

    Objectives: Prolactinoma is a common intracranial tumor with a high incidence and serious harm to human health. At present, there is only one therapeutic drug in China, bromocriptine, and the Chinese herb Prunella vulgaris L. (P. vulgaris)(PV) has shown certain anti-prolactinoma effects in the early stage. We expect to develop a candidate drug against prolactinoma. Materials and Methods: First, the extracts of P. vulgaris L.(PVE)were extracted with water, and the cell proliferation test of rat pituitary tumor cells MMQ was checked by the Cell Counting Kit-8 (CCK-8) assay. Then, core targets and correlative pathways were selected by the “protein–protein interaction” (PPI) network and the “PV–Target–Prolactinoma” network. The core targets and main components simulate the binding by molecular docking. Finally, the PVE and MMQ cells were used to verify the results. Results: Through the CCK-8 assay, the PVE inhibited the proliferation of MMQ cells. From the network pharmacology, the 21 targets, 9 signaling pathways, and 20 gene ontology (GO) projects were attained (p < 0.05). As a result the estrogen receptor α (ESR1), RAC-alpha serine/threonine-protein kinase(AKT1), and mitogen-activated protein kinase 3(MAPK3)were the core targets of protein against prolactinomas, which was in line with western blotting analysis. Conclusion: Our findings demonstrate that the PVE was verified against prolactinomas through the ESR1, MAPK3 targets, and the phosphoinositide 3-kinase/protein kinase B pathway.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Meng, J., Ni, P., Cao, Y., Zhang, Y., Wang, X., Zhang, H., & Chen, Y. (2024). Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma. Pharmacognosy Magazine, 20(1), 127–136. https://doi.org/10.1177/09731296231189329